A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Public ClinicalTrials.gov record NCT05797610. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Study identification
- NCT ID
- NCT05797610
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 459 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2023 (Actual)
- Primary completion
- May 25, 2028 (Estimated)
- Completion
- Aug 31, 2029 (Estimated)
- Last update posted
- Oct 5, 2026
2023 – 2029
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Nephrology Research Clinic | Birmingham | Alabama | 35233 | — |
| Kidney Disease Medical Group Inc-1505 Wilson Ter | Glendale | California | 91206-4032 | — |
| Academic Medical Research Institute - Los Angeles | Los Angeles | California | 90022 | — |
| UCLA University of California Los Angeles | Los Angeles | California | 90095-8361 | — |
| North America Research Institute-San Dimas | San Dimas | California | 91773 | — |
| Central Florida Kidney Specialists | Orlando | Florida | 32806 | — |
| L&C Professional Medical Research Institute | West Miami | Florida | 33144 | — |
| Cowry Medical Group LLC | Acworth | Georgia | 30101 | — |
| Care Institute Idaho Kidney Institute | Idaho Falls | Idaho | 83402 | — |
| Nephrology Associates of Northern Illinois | Hinsdale | Illinois | 60521 | — |
| Massachussets General Hospital | Boston | Massachusetts | 02114 | — |
| Sierra Nevada Nephrology Consultants | Reno | Nevada | 89511 | — |
| North Carolina Nephrology, PA | Raleigh | North Carolina | 27609 | — |
| Texas Kidney Institute - Dallas | Dallas | Texas | 75231 | — |
| Pioneer Research Solutions | Houston | Texas | 077099 | — |
| Prolato Clinical Research Center | Houston | Texas | 77054 | — |
| R & H Clinical Research | Katy | Texas | 77449 | — |
| Revival Research Institute - McKinney | McKinney | Texas | 75071 | — |
| Nephrology Associates of Northern Virginia Inc | Fairfax | Virginia | 22033 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05797610, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05797610 live on ClinicalTrials.gov.